Robert G. Conway - 28 Jun 2023 Form 4 Insider Report for AGILE THERAPEUTICS INC

Role: Chief Supply Chain Officer
Signature: /s/ Geoffrey P. Gilmore. Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 28 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 30 Jun 2023, 16:37:08 UTC
Previous filing: 14 Nov 2022
Next filing: 26 Aug 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGRX	Common Stock	Award	$0	+13,500	+46552%	$0.000000	13,529	28 Jun 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGRX	Employee Stock Option (Right to Buy)	Award	$0	+4,500		$0.000000	4,500	28 Jun 2023	Common Stock	4,500	$2.48	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSU") which were granted on June 28, 2023. The RSUs will vest in four equal installments over four years upon the anniversary of the grant, such that the RSUs will be fully vested on June 28, 2027.
F2	On April 10, 2023, the Issuer completed a one-for-fifty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split.
F3	This option was granted on June 28, 2023. 25% of the shares subject to the stock option vest on June 28, 2024, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on June 28, 2027.